Relation of nocturnal melatonin levels to serum matrix metalloproteinase-9 concentrations in patients with myocardial infarction

Alberto Dominguez-Rodriguez, Pedro Abreu-Gonzalez, Martín J. Garcia-Gonzalez, Russel J Reiter

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Introduction: The aims of the present study were to characterize the day/night variation of matrix metalloproteinase (MMP)-9 in patients who have developed ST-segment elevation myocardial infarction (STEMI), in response to light/dark differences in circulating melatonin and to assess whether melatonin, a day/night variation regulator, modulates the nocturnal inflammatory changes in patients who have STEMI. Methods: The study included 75 patients diagnosed with STEMI and 75 control subjects. Each subject was studied under strictly controlled light/dark conditions. Blood samples for measurement of MMP-9 and melatonin were collected at 09:00 a.m. (light period) and 02:00 a.m. (dark period). Results: In patients with STEMI, melatonin concentrations maintained a light/dark variation but the difference between nocturnal and diurnal levels was smaller than that in controls (p < 0.001). In contrast to melatonin, serum MMP-9 concentrations showed no day/night variation in control subjects. MMP-9 concentrations were significantly higher in patients with STEMI than in control subjects. In the STEMI subjects, MMP-9 serum concentrations in the light period were significantly higher than those during the dark phase (291.1 ± 59.5 vs. 261.8 ± 57.8 ng/ml, p < 0.01). Furthermore in the control subjects there was no correlation between MMP-9 and melatonin levels, while in the STEMI group there was a significant correlation between these parameters (Pearson's r = 0.40, p < 0.0004). Conclusions: Our results suggest that the light/dark variations in endogenous MMP-9 production in patients who have STEMI might be associated, at least in part, to the day/night variation of melatonin.

Original languageEnglish (US)
Pages (from-to)361-366
Number of pages6
JournalThrombosis Research
Volume120
Issue number3
DOIs
StatePublished - 2007

Fingerprint

Matrix Metalloproteinase 9
Melatonin
Myocardial Infarction
Light
Serum

Keywords

  • Day/night variation
  • Matrix metalloproteinase-9
  • Melatonin
  • Myocardial infarction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Hematology

Cite this

Relation of nocturnal melatonin levels to serum matrix metalloproteinase-9 concentrations in patients with myocardial infarction. / Dominguez-Rodriguez, Alberto; Abreu-Gonzalez, Pedro; Garcia-Gonzalez, Martín J.; Reiter, Russel J.

In: Thrombosis Research, Vol. 120, No. 3, 2007, p. 361-366.

Research output: Contribution to journalArticle

Dominguez-Rodriguez, Alberto ; Abreu-Gonzalez, Pedro ; Garcia-Gonzalez, Martín J. ; Reiter, Russel J. / Relation of nocturnal melatonin levels to serum matrix metalloproteinase-9 concentrations in patients with myocardial infarction. In: Thrombosis Research. 2007 ; Vol. 120, No. 3. pp. 361-366.
@article{226998b026e6445489f501bcb1120950,
title = "Relation of nocturnal melatonin levels to serum matrix metalloproteinase-9 concentrations in patients with myocardial infarction",
abstract = "Introduction: The aims of the present study were to characterize the day/night variation of matrix metalloproteinase (MMP)-9 in patients who have developed ST-segment elevation myocardial infarction (STEMI), in response to light/dark differences in circulating melatonin and to assess whether melatonin, a day/night variation regulator, modulates the nocturnal inflammatory changes in patients who have STEMI. Methods: The study included 75 patients diagnosed with STEMI and 75 control subjects. Each subject was studied under strictly controlled light/dark conditions. Blood samples for measurement of MMP-9 and melatonin were collected at 09:00 a.m. (light period) and 02:00 a.m. (dark period). Results: In patients with STEMI, melatonin concentrations maintained a light/dark variation but the difference between nocturnal and diurnal levels was smaller than that in controls (p < 0.001). In contrast to melatonin, serum MMP-9 concentrations showed no day/night variation in control subjects. MMP-9 concentrations were significantly higher in patients with STEMI than in control subjects. In the STEMI subjects, MMP-9 serum concentrations in the light period were significantly higher than those during the dark phase (291.1 ± 59.5 vs. 261.8 ± 57.8 ng/ml, p < 0.01). Furthermore in the control subjects there was no correlation between MMP-9 and melatonin levels, while in the STEMI group there was a significant correlation between these parameters (Pearson's r = 0.40, p < 0.0004). Conclusions: Our results suggest that the light/dark variations in endogenous MMP-9 production in patients who have STEMI might be associated, at least in part, to the day/night variation of melatonin.",
keywords = "Day/night variation, Matrix metalloproteinase-9, Melatonin, Myocardial infarction",
author = "Alberto Dominguez-Rodriguez and Pedro Abreu-Gonzalez and Garcia-Gonzalez, {Mart{\'i}n J.} and Reiter, {Russel J}",
year = "2007",
doi = "10.1016/j.thromres.2006.10.010",
language = "English (US)",
volume = "120",
pages = "361--366",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - Relation of nocturnal melatonin levels to serum matrix metalloproteinase-9 concentrations in patients with myocardial infarction

AU - Dominguez-Rodriguez, Alberto

AU - Abreu-Gonzalez, Pedro

AU - Garcia-Gonzalez, Martín J.

AU - Reiter, Russel J

PY - 2007

Y1 - 2007

N2 - Introduction: The aims of the present study were to characterize the day/night variation of matrix metalloproteinase (MMP)-9 in patients who have developed ST-segment elevation myocardial infarction (STEMI), in response to light/dark differences in circulating melatonin and to assess whether melatonin, a day/night variation regulator, modulates the nocturnal inflammatory changes in patients who have STEMI. Methods: The study included 75 patients diagnosed with STEMI and 75 control subjects. Each subject was studied under strictly controlled light/dark conditions. Blood samples for measurement of MMP-9 and melatonin were collected at 09:00 a.m. (light period) and 02:00 a.m. (dark period). Results: In patients with STEMI, melatonin concentrations maintained a light/dark variation but the difference between nocturnal and diurnal levels was smaller than that in controls (p < 0.001). In contrast to melatonin, serum MMP-9 concentrations showed no day/night variation in control subjects. MMP-9 concentrations were significantly higher in patients with STEMI than in control subjects. In the STEMI subjects, MMP-9 serum concentrations in the light period were significantly higher than those during the dark phase (291.1 ± 59.5 vs. 261.8 ± 57.8 ng/ml, p < 0.01). Furthermore in the control subjects there was no correlation between MMP-9 and melatonin levels, while in the STEMI group there was a significant correlation between these parameters (Pearson's r = 0.40, p < 0.0004). Conclusions: Our results suggest that the light/dark variations in endogenous MMP-9 production in patients who have STEMI might be associated, at least in part, to the day/night variation of melatonin.

AB - Introduction: The aims of the present study were to characterize the day/night variation of matrix metalloproteinase (MMP)-9 in patients who have developed ST-segment elevation myocardial infarction (STEMI), in response to light/dark differences in circulating melatonin and to assess whether melatonin, a day/night variation regulator, modulates the nocturnal inflammatory changes in patients who have STEMI. Methods: The study included 75 patients diagnosed with STEMI and 75 control subjects. Each subject was studied under strictly controlled light/dark conditions. Blood samples for measurement of MMP-9 and melatonin were collected at 09:00 a.m. (light period) and 02:00 a.m. (dark period). Results: In patients with STEMI, melatonin concentrations maintained a light/dark variation but the difference between nocturnal and diurnal levels was smaller than that in controls (p < 0.001). In contrast to melatonin, serum MMP-9 concentrations showed no day/night variation in control subjects. MMP-9 concentrations were significantly higher in patients with STEMI than in control subjects. In the STEMI subjects, MMP-9 serum concentrations in the light period were significantly higher than those during the dark phase (291.1 ± 59.5 vs. 261.8 ± 57.8 ng/ml, p < 0.01). Furthermore in the control subjects there was no correlation between MMP-9 and melatonin levels, while in the STEMI group there was a significant correlation between these parameters (Pearson's r = 0.40, p < 0.0004). Conclusions: Our results suggest that the light/dark variations in endogenous MMP-9 production in patients who have STEMI might be associated, at least in part, to the day/night variation of melatonin.

KW - Day/night variation

KW - Matrix metalloproteinase-9

KW - Melatonin

KW - Myocardial infarction

UR - http://www.scopus.com/inward/record.url?scp=34249947798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249947798&partnerID=8YFLogxK

U2 - 10.1016/j.thromres.2006.10.010

DO - 10.1016/j.thromres.2006.10.010

M3 - Article

C2 - 17126384

AN - SCOPUS:34249947798

VL - 120

SP - 361

EP - 366

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

IS - 3

ER -